Product apis-jak-stat

Home > products > apis> jak-stat

Catalog	name	Description	price
R-R-2297	ZM39923 hydrochloride CAS No.1021868-92-7	ZM39923 hydrochloride/CAS No.1021868-92-7 is a JAK3 inhibitor, with a pIC50 of 7.1; ZM39923 hydrochloride also potently inhibits tissue transglutaminase (TGM2) with an IC50 of 10 nM.	price>
R-R-2298	Cerdulatinib hydrochloride CAS No.1369761-01-2	Cerdulatinib hydrochloride (PRT062070)/CAS No.1369761-01-2 is a selective, oral active and reversible ATP-competitive inhibitor of dual SYK and JAK, with IC50s of 32 nM, 0.5 nM, 12 nM, 6 nM and 8 nM for SYK and Tyk2, JAK1, 2, 3, respectively. Cerdulatinib hydrochloride could be used to research autoimmune disease and B-cell malignancies.	price>
R-R-2300	Londamocitinib CAS No.2241039-81-4	Londamocitinib (AZD4604; JAK1-IN-7)/CAS No.2241039-81-4 is a Janus-associated kinase 1 (JAK1) inhibitor extracted from patent WO2018134213A1, Example 63, has an anti-inflammatory effect.	price>
R-R-2301	Ifidancitinib CAS No.1236667-40-5	Ifidancitinib (ATI-50002)/CAS No.1236667-40-5 is a potent and selective inhibitor of JAK kinases 1/3. Ifidancitinib can be used in studies of allergies, asthma and autoimmune diseases.	price>
R-R-2302	Protosappanin A CAS No.102036-28-2	Protosappanin A (PTA)/CAS No.102036-28-2, an immunosuppressive ingredient and major biphenyl compound isolated from Caesalpinia sappan L, suppresses JAK2/STAT3-dependent inflammation pathway through down-regulating the phosphorylation of JAK2 and STAT3.	price>
R-R-2303	Brepocitinib CAS No.1883299-62-4	Brepocitinib (PF-06700841)/CAS No.1883299-62-4 is a potent dual Janus kinase 1 (JAK1) and TYK2 inhibitor with IC50s of 17 nM and 23 nM, respectively. Brepocitinib also inhibits JAK2 and JAK3 with IC50s of 77 nM and 6.49 μM, respectively.	price>
R-R-2304	TCS 21311 CAS No.1260181-14-3	TCS 21311 (NIBR3049)/CAS No.1260181-14-3 is a potent, highly selective JAK3 inhibitor with an IC50 of 8 nM, it displays >100-fold selectivity over JAK1, JAK2 and TYK2. TCS 21311 (NIBR3049) inhibits PKCα, PKCθ, and GSK3β with IC50s of 13, 68, and 3 nM, respectively.	price>
R-R-2305	JAK2-IN-7 CAS No.2593402-36-7	JAK2-IN-7/CAS No.2593402-36-7 is a selective JAK2 inhibitor with IC50s of 3, 11.7, and 41 nM for JAK2, SET-2, and Ba/F3V617F cells, respectively. JAK2-IN-7 possesses >14-fold selectivity over JAK1, JAK3, FLT3. JAK2-IN-7 stimulates cell cycle arrest in the G0/G1 phase and induces tumor cellapoptosis. Antitumor activities.	price>
R-R-2306	JAK-IN-5 hydrochloride CAS No.2751323-21-2	JAK-IN-5 hydrochloride/CAS No.2751323-21-2 is an inhibitor of JAK extracted from patent US20170121327A1, compound example 283.	price>
R-R-2307	BI-1622 CAS No.2681392-19-6	BI-1622/CAS No.2681392-19-6 is an orally active, potent and highly selective HER2 (ERBB2) inhibitor, with an IC50 of 7 nM. BI-1622 shows greater than 25-fold selectivity over EGFR. BI-1622 shows high antitumor efficacy in vivo in xenograft mouse tumor models with engineered H2170 and PC9 cells and had a favorable agent metabolism and pharmacokinetics profile.	price>

...